Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00997243 · OUTCOME

Perform Exploratory Studies of AZA-triphosphate With Global DNA Methylation

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes · Source last updated 2017-05-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
up to 5 years

Analysis population: No participants were analyzed due to withdrawal of the investigational agent by the company.

Groups in this outcome

5-azacytidine and Lintuzumab

Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC daily on days 1-7. Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
5-azacytidine and Lintuzumab0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
groups
  1. description
    Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC daily on days 1-7. Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7.
    id
    OG000
    title
    5-azacytidine and Lintuzumab
population Description
No participants were analyzed due to withdrawal of the investigational agent by the company.
reporting Status
POSTED
time Frame
up to 5 years
title
Perform Exploratory Studies of AZA-triphosphate With Global DNA Methylation
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice